Methods of using antibodies against human IL-22
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
1. A method of treating an interleukin-22 (IL-22)-associated disorder, in a subject, wherein the IL-22-associated disorder is atopic dermatitis, said method comprising, administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to human IL-22, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating the disorder, wherein the antibody, or antigen-binding fragment thereof, comprises a V H domain comprising three complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO:620, 621, and 622 and a V L domain comprising three CDRs comprising the amino acid sequences of SEQ ID NO: 623, 624, and 625, or wherein the antibody, or antigen-binding fragment thereof, comprises a V H domain comprising three complementary determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO:602, 603, and 604 and a V L domain comprising three CDRs comprising the amino acid sequences of SEQ ID NO:605, 606, and 607.
2. The method of claim 1 , wherein the V L domain comprises the amino acid sequence of SEQ ID NO: 600 or 618.
3. The method of claim 2 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO: 599 or 617.
4. The method of claim 1 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO: 617 and the V L domain comprises the sequence of SEQ ID NO: 618.
5. The method of claim 1 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO: 599 and the V L domain comprises the sequence of SEQ ID NO: 600.
6. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, has an association constant for human IL-22 of at least 10 10 M −1 .
7. The method of claim 6 , wherein the association constant for human IL-22 is at least 10 11 M −1 .
8. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, blocks IL-22 mediated BAF3 cell proliferation with an IC 50 of 150 pM or less, wherein the BAF3 cells comprise a human IL-22 receptor.
9. The method of claim 8 , wherein the antibody, or antigen-binding fragment thereof, blocks IL-22 mediated BAF3 cell proliferation with an IC 50 of 100 pM or less.
10. The method of claim 1 , wherein the antibody, or antigen-binding fragment thereof, blocks IL-22 mediated GROa secretion from HT29 cells with an IC 50 of 1 nM or less.
11. The method of claim 10 , wherein the antibody, or antigen-binding fragment thereof, blocks IL-22 mediated GROa secretion from HT29 cells with an IC 50 of 150 pM or less.
12. The method of claim 1 , wherein the subject is a mammal.
13. The method of claim 1 , wherein the subject is a human.
14. The method of claim 13 , wherein the antibody is administered in a range chosen from 1 μg/kg to 20 mg/kg, 1 μg/kg to 10 mg/kg, 1 μg/kg to 1 mg/kg, 10 μg/kg to 1 mg/kg, 10 μg/kg to 100 μg/kg, 100 μg to 1 mg/kg, 250 μg/kg to 2 mg/kg, 950 μg/kg to 1 mg/kg, 500 μg/kg to 2 mg/kg, 1 mg/kg to 5 mg/kg, 5 mg/kg to 10 mg/kg, 10 mg/kg to 20 mg/kg, 10 mg/kg to 25 mg/kg, and 20 mg/kg to 30 mg/kg.
15. A method of treating atopic dermatitis in a subject, said method comprising, administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to human IL-22, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating the atopic dermatitis, wherein the antibody, or antigen-binding fragment thereof, comprises a V H domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:617 and a V L domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:618 or wherein the antibody, or antigen-binding fragment thereof, comprises a V H domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:599 and a V L domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:600.
16. The method of claim 15 , wherein the V H domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:617 and the V L domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:618 or wherein the V H domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:599 and the V L domain comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:600.
17. The method of claim 15 , wherein the V H domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:617 and the V L domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:618 or wherein the V H domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:599 and the V L domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:600.
18. The method of claim 15 , wherein the V H domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:617 and the V L domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:618 or wherein the V H domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:599 and the V L domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:600.
19. The method of claim 15 , wherein the V H domain differs by no more than 5 amino acids from the amino acid sequence of SEQ ID NO:617 and wherein the V L domain differs by no more than 5 amino acids from the amino acid sequence of SEQ ID NO:618 or wherein the V H domain differs by no more than 5 amino acids from the amino acid sequence of SEQ ID NO:599 and wherein the V L domain differs by no more than 5 amino acids from the amino acid sequence of SEQ ID NO:600.
20. The method of claim 15 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO:617 and the V L domain comprises the amino acid sequence of SEQ ID NO:618.
21. The method of claim 15 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO:599 and the V L domain comprises the amino acid sequence of SEQ ID NO:600.
22. A method of treating atopic dermatitis in a subject, said method comprising, administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to human IL-22, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating the atopic dermatitis, wherein the antibody, or antigen-binding fragment thereof, comprises a V H domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:599 or SEQ ID NO:617.
23. The method of claim 22 , wherein the V H domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:599 or SEQ ID NO:617.
24. The method of claim 22 , wherein the V H domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:599 or SEQ ID NO:617.
25. The method of claim 22 , wherein the V H domain comprises the amino acid sequence of SEQ ID NO:599 or SEQ ID NO:617.
26. A method of treating atopic dermatitis in a subject, said method comprising, administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to human IL-22, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating the atopic dermatitis, wherein the antibody, or antigen-binding fragment thereof, comprises a V L domain comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:600 or SEQ ID NO:618.
27. The method of claim 26 , wherein the V L domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:600 or SEQ ID NO:618.
28. The method of claim 26 , wherein the V L domain comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:600 or SEQ ID NO:618.
29. The method of claim 26 , wherein the V L domain comprises the amino acid sequence of SEQ ID NO:600 or SEQ ID NO:618.